Sensus Healthcare Inc
NASDAQ:SRTS

Watchlist Manager
Sensus Healthcare Inc Logo
Sensus Healthcare Inc
NASDAQ:SRTS
Watchlist
Price: 4.44 USD -1.11% Market Closed
Market Cap: $73.1m

Sensus Healthcare Inc
Other Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Sensus Healthcare Inc
Other Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Items CAGR 3Y CAGR 5Y CAGR 10Y
Sensus Healthcare Inc
NASDAQ:SRTS
Other Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Other Items
-$1.8B
CAGR 3-Years
-7%
CAGR 5-Years
N/A
CAGR 10-Years
-1%
Stryker Corp
NYSE:SYK
Other Items
-$4.1B
CAGR 3-Years
-21%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Abbott Laboratories
NYSE:ABT
Other Items
-$251m
CAGR 3-Years
N/A
CAGR 5-Years
-46%
CAGR 10-Years
N/A
IDEXX Laboratories Inc
NASDAQ:IDXX
Other Items
$2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Intuitive Surgical Inc
NASDAQ:ISRG
Other Items
$1.2B
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Sensus Healthcare Inc
Glance View

Market Cap
73.1m USD
Industry
Health Care

Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The company is headquartered in Boca Raton, Florida and currently employs 37 full-time employees. The company went IPO on 2016-06-03. The firm is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. The firm uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The firm incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100 Plus and SRT-100 Vision. SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. Its SRT-100 Plus offers remote diagnostics solutions, including operation tracking.

SRTS Intrinsic Value
1.67 USD
Overvaluation 62%
Intrinsic Value
Price $4.44

See Also

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett